Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

References

• BYETTA Prescribing Information. Amylin Pharmaceuticals, Inc and Eli Lilly and Co; 2008 [cited 06 October 2008]. Available from: http://www.byettahcp.com/hcp/index.jsp
   Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• JANUVIA Prescribing Information. Merck and Co., Inc; 2008 [cited 06 October 2008]. Available from: http://www.januvia.com/sitagliptin/januvia/consumer/pi/index.jsp
   Google Scholar
• Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88
   PubMed Web of Science ®Google Scholar
• Ahmad SR, Swann J. Exenatide and rare adverse events. N Eng J Med 2008;358:1970-1
   PubMed Web of Science ®Google Scholar
• Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006;29:471
   PubMed Web of Science ®Google Scholar
• BYETTA product label. US Food and Drug Administration; 2008 [cited 25 February 2008]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
   Google Scholar
• MedWatch Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. United States Food and Drug Administration MedWatch;2008 [cited 11 Feb 2009]. Available from: http://www.nlm.nih.gov/bsd/uniform_requirements.html
   Google Scholar
• Bloomgren G, Braun D, Kolterman O. Exenatide and rare adverse events. N Eng J Med 2008;358:1971-2
   Web of Science ®Google Scholar
• Adverse Event Reporting System (AERS). United States Food and Drug Administration; 2008 [cited 06 October 2008]. Available from: http://www.fda.gov/cder/aers/default.htm
   Google Scholar
• The future of drug safety: promoting and protecting the health of the public. Institute of Medicine of the National Academies; 2007 [cited 06 October 2008]. Available from: http://fermat.nap.edu/books/0309103045/html/15.html
   Google Scholar
• Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998;20:40
   PubMed Web of Science ®Google Scholar
• Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986;81:49-55
   PubMed Web of Science ®Google Scholar
• Strom BL, Kimmel SE. Textbook of Pharmacoepidemiology. Chichester, UK; Hoboken, NJ: John Wiley, 2006:xiv, 498
   Google Scholar
• Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Advances in Inflammation Research, Vol. 6. New York: Raven Press, 1984
   Google Scholar
• Platt R, Madre L, Reynolds R, et al. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 2008;17:1175-82
   PubMed Web of Science ®Google Scholar
• National population estimates for the 2000s -- Monthly Postcensal Resident Population, by single year of age, sex, race, and Hispanic origin. US Census; 2007 [cited 09 February 2009]. Available from: http://www.census.gov/popest/national/asrh/2007-nat-res.html
   Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs. Pharmacoeconomics 2007;25:481-96
   PubMed Web of Science ®Google Scholar
• Baldessarini R, Henk H, Sklar A, et al. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008;59:1175-83
   PubMed Web of Science ®Google Scholar
• Miller DP, Alfredson TD, Cook SF, et al. Incidence of colon ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol 2003;98:1117-22
   PubMed Web of Science ®Google Scholar
• Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002;11:477-86
   PubMed Web of Science ®Google Scholar
• Loughlin JE, Alfredson TD, Ajene AN, et al. Risk of respiratory events in a retrospective cohort of patients receiving inhaled zanamivir. Clin Ther 2002;24:1786-99
   PubMed Web of Science ®Google Scholar
• Loughlin JE, Cole JA, Rothman KJ, et al. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol 2002;88:319-25
   PubMed Web of Science ®Google Scholar
• Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac side effects among cisapride users in the United Kingdom and Canada. Am J Med 1999;107:356-62
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83
   PubMed Web of Science ®Google Scholar
• Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93
   PubMed Web of Science ®Google Scholar
• Connors Jr AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996;276:889-97
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference, Cary, NC. Cary, NC: SAS Institute Inc., 2001:214-26
   Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• Sclar DA, Chin A, Skaer TL, et al. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 1991;13:489-95
   PubMed Web of Science ®Google Scholar
• Sclar DA, Skaer TL, Chin A, et al. Utility of a transdermal delivery system for antihypertensive therapy. Part 1. Am J Med 1991;91:50-6S
   Web of Science ®Google Scholar
• Yadav D, Dhir R. How accurate are ICD-9 codes for acute (AP) and chronic (CP) pancreatitis? A large VA hospital experience (Abstract). Pancreas 2006;33:508
   Google Scholar
• Walker AM. Pattern recognition in health insurance claims databases. Pharmacoepidemiol Drug Saf 2001;10:393-7
   PubMed Web of Science ®Google Scholar
• Crystal S, Akincigil A, Bilder S, et al. Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care 2007;45:58-65
   PubMed Web of Science ®Google Scholar
• Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005;14:465-76
   PubMed Web of Science ®Google Scholar
• Rodgers A, MacMahon S. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials. Thromb Haemost 1995;73:167-71
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
   PubMed Web of Science ®Google Scholar